Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive study tests diabetes drug for heart attack recovery

NCT ID NCT07198191

Knowledge-focused Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a common diabetes medicine (SGLT2 inhibitor) can help prevent future heart problems in people with type 2 diabetes who have had a heart attack. Researchers will compare health records of 200,000 adults in Korea who took either an SGLT2 inhibitor or another diabetes drug after their heart attack. The goal is to see which group has fewer deaths, heart attacks, or strokes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2014

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients (≥19 years) with type 2 diabetes mellitus who were hospitalized for acute myocardial infarction in South Korea between September 2014 and June 2021. Eligible patients were identified from the Korean National Health Insurance Service database, with follow-up available through June 2022.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥19 years * Hospitalization with a primary diagnosis of acute myocardial infarction between September 2014 and June 2021 * Diagnosis of type 2 diabetes mellitus (T2DM) * Prescription of either an SGLT2 inhibitor or a DPP4 inhibitor after index AMI Exclusion Criteria: * Diagnosis of type 1 diabetes mellitus * Gestational diabetes mellitus * End-stage renal disease (ESRD) or history of kidney transplantation * No use of either SGLT2 inhibitor or DPP4 inhibitor after index AMI * Short-term use of SGLT2 inhibitor or DPP4 inhibitor (less than 30 days) * Concomitant use of SGLT2 inhibitor and DPP4 inhibitor * Incomplete or missing data for key study variables

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction (AMI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute myocardial infarction heart failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute myocardial infarction (AMI) Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Yongin Severance Hospital, Yonsei University Health System

    Yongin, Gyeonggi-do, 16995, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.